Analysis of the Application of Sacubitril-Valsartan in Inpatients with Heart Failure in a Hospital

Abstract

Abstract:

〔Abstract〕 Objective： To analyze the application of sacubitril-valsartan in inpatients with heart failure in the First Affiliated Hospital of Dali University， so as to provide a basis for clinical rational use of the drug. Methods：The hospital information system was used to collect the basic information of inpatients who used sacubitril-valsartan from June to December 2020， and the application of the drug was retrospectively analyzed. Results： A total of 213 patients with indications were enrolled， and 42 cases had relative drug contraindications. The initial dose or frequency were unreasonable in 49 cases， and the target dose was not up to standard in 173 cases. There were 93 cases treated with ACEI or ARB converted to the application of sacubitril-valsartan， and 28 cases were not properly converted. Compared to the situation before treatment， the cardiac function of patients without relative contraindications improved significantly， while the renal function of patients with relative contraindications improved obviously. 49 cases had adverse drug reaction. Conclusion： There are some unreasonable situations in the use of sacubitril-valsartan in patients with heart failure in this hospital， such as relative medication contraindications， low initial dose， low rate of target dose reaches to standard， and inappropriate drug timing of drug conversion. It is suggested that medical institutions should standardize the clinical application of the drug.

Key words:

"> font-size:10.5pt, ">sacubitril-valsartan, heart failure, rational drug use, effectiveness, safety

CLC Number:

Li Qiujing, Guo Yu, Zhao Yanju, Shen Lei.

Analysis of the Application of Sacubitril-Valsartan in Inpatients with Heart Failure in a Hospital [J]. Journal of Dali University, 2022, 7(10): 22-27.

References

〔1〕李小荣，郑旭辉，李新立．血管紧张素受体脑啡肽酶抑制剂在心力衰竭治疗中的研究进展及展望〔J〕．中国循环杂志， 2018， 33（2）： 195-198.

〔2〕 YANCY C W， JESSUP M， BOZKURT B，et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure： A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America〔J〕. J Card Fail，2017，23（8）： 628-651.

〔3〕国家卫生计生委合理用药专家委员会，中国药师协会．心力衰竭合理用药指南（第2版）〔J〕. 中国医学前沿杂志（电子版）， 2019， 11（7）： 1-78.

〔4〕 PONIKOWSKI P， VOORS A A， ANKER S D，et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure： The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology （ESC）.Deve-loped with the Special Contribution of the Heart Failure Association（HFA） of the ESC〔J〕. Eur J Heart Fail，2016， 18（8）： 891-975.

〔5〕 MCMURRAY J J， PACKER M， DESAI A S， et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure〔J〕. N Engl J Med，2014，371（11）：993-1004.

〔6〕陈存芳，贾博，江珊，等．沙库巴曲缬沙坦治疗射血分数中间值心力衰竭患者的疗效及预后〔J〕. 中国新药与临床杂志，2020，39（2）： 88-92.

〔7〕 SOLOMON S D， ZILE M， PIESKE B， et al. The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction： A Phase 2 Double-Blind Randomised Controlled Trial〔J〕. Lancet，2012， 380： 1387-1395.

〔8〕 VADUGANATHAN M， CLAGGETT B L， DESAI A S，et al. Prior Heart Failure Hospitalization， Clinical Outcomes， and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF〔J〕. J Am Coll Cardiol， 2020， 75（3）：245-254.

〔9〕 DU A X， WESTERHOUT C M， MCALISTER F A， et al. Titration and Tolerability of Sacubitril/Valsartan for Patients with Heart Failure in Clinical Practice〔J〕. J Cardiovasc Pharmacol，2019，73（3）：149-154.

〔10〕 MARTENS P， LAMBEETS S， LAU C W，et al. Impact of Sacubitril/Valsartan on Heart Failure Admissions：Insights from Real-World Patient Prescriptions〔J〕. Acta Cardiol，2019，74（2）： 115-122.

〔11〕 VON LUEDER T G， SANGARALINGHAM S J， WANG B H，et al. Renin-Angiotensin Blockade Combined with Natriuretic Peptide System Augmentation： Novel Therapeutic Concepts to Combat Heart Failure〔J〕. Circ Heart Fail， 2013， 6（3）：594-605.

〔12〕 YANCY C W ， JANUZZI J L ， ALLEN L A ， et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment： Answers to 10 Pivotal Issues about Heart Failure with Reduced Ejection Fraction〔J〕.J Am Coll Cardiol， 2017：S073510971741641X.

〔13〕 MCMURRAY J J， PACKER M， DESAI A S， et al. Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure： Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Mortality in Heart Failure Trial（PARADIGM-HF）〔J〕. Eur J Heart Fail， 2013，15（9）：1062-1073.

[1]	Li Jing, Ling Haowei, Shi Kaixuan, Liu Rong, Xiao Chaojiang, Jiang Bei, . Study on Chemical Constituents of the Root of Agapetes lacei var. tomentella [J]. Journal of Dali University, 2023, 8(8): 1-5.
[2]	Ling Haowei, Li Jing, Shi Kaixuan, Liu Rong, Xiao Chaojiang, Jiang Bei, . Study on Chemical Constituents of Gentiana nanobella [J]. Journal of Dali University, 2023, 8(8): 6-10.
[3]	Shi Kaixuan, Li Jing, Ling Haowei, Liu Rong, Xiao Chaojiang, Jiang Bei, . Study on Chemical Constituents of Leptodermis pilosa [J]. Journal of Dali University, 2023, 8(8): 11-14.
[4]	Qin Zikang, Guo Haihui, Shan Fang, Wu Lei, Wang Fusheng. Synthesis of L-5-Hydroxytryptophan Derivatives [J]. Journal of Dali University, 2023, 8(8): 15-20.
[5]	Shan Fang, Guo Haihui, Qin Zikang, Li Chunxu, Wang Fusheng. Synthesis of Gentiournoside D Amide Derivatives [J]. Journal of Dali University, 2023, 8(8): 21-24.
[6]	Lai Yuxia, Guo Haihui, Qin Zikang, Shan Fang, Wang Fusheng. Optimization of Ｓelective Ester Hydrolysis Conditions for Depresteroside [J]. Journal of Dali University, 2023, 8(8): 25-29.
[7]	Lu Xixing, Zhu Ling, Wu Hao, Zhang Chenggui, Yang Yongshou, Chen Zhipeng, Liu Heng, . Chemical Composition Analysis and Multicomponent Content Determination of Extracts of Periplaneta americana from Different Breeding Plants [J]. Journal of Dali University, 2023, 8(8): 30-38.
[8]	Su Baoshun, Liu Zhitong. Preliminary Study on Antibacterial Effect and Active Parts of Dobinea delavayi [J]. Journal of Dali University, 2023, 8(8): 39-43.
[9]	Li Xiaoji, Li Guorong. Construction and Effectiveness of the Pharmaceutical Control System of Injection Proton Pump Inhibitors [J]. Journal of Dali University, 2023, 8(8): 44-48.
[10]	Ye Shengying, Wang Xinrui, Gao Jingwen, Qin Yan. The Protective Effect of Ghrelin on High Glucose-Induced Ｈepatocellular Injury [J]. Journal of Dali University, 2023, 8(8): 49-53.
[11]	Deng Wenbin, Huang Shiqiong, Wang Xue, Li Lihua. Effects of High Salt Intervention on Proliferation and Migration of Human Aortic Vascular Smooth Muscle Cell [J]. Journal of Dali University, 2023, 8(8): 54-58.
[12]	Zhi Hongfang, Chen Xin, Zhang Jianyan, Wang Chengcheng, Zhang Yun, Yang Xuantao. Expression of RIP140 and LCOR in High-Grade Cervical Intraepithelial Neoplasia [J]. Journal of Dali University, 2023, 8(8): 59-63.
[13]	Wu Maofang, Shi Wen, Xiao Shouyong, Cai Jingjing, Liu Zengping, Fang Hong. Propensity Score Matching Analysis of Postoperative Radiotherapy in Patients with Stage ⅢA/N2 Non-Small Cell Lung Carcinoma [J]. Journal of Dali University, 2023, 8(8): 64-70.
[14]	Xiao Min, Xiong Miaomiao, Cheng Mingjing, Cui Xiuyu, Zhao Yuanqi, Zhao Weidong. Scientometric Analysis of Ferroptosis Literature Based on Web of Science #br# [J]. Journal of Dali University, 2023, 8(8): 71-77.
[15]	Rao Yanhua, Wu Xingjun, Quan Yuan, Guan Qingni, Wang Suorong, Tian Ying. Study on the Elderly Care Career-Selection Motivation and Influencing Factors of Vocational Nursing Students [J]. Journal of Dali University, 2023, 8(8): 78-83.